EURACTIV - Young Europeans arrived in the European Parliament with a clear message: they don't just want a seat at the table, they want their priorities written into EU policy. Read more

EU PERSPECTIVES - During the latest political trilogue on 10 and 11 November, co-legislators confirmed that they had reached a preliminary political agreement on incentives for the development of priority antimicrobials. This includes the Council's mandate as a baseline for the Voucher and the Parliament's voluntary subscription model. Read more

EU PERSPECTIVES - Eli Lilly and Company's decision to invest $3bn (€2.6bn) in a next-generation manufacturing site in Katwijk, the Netherlands, offers a counterpoint to the prevailing narrative of Europe losing ground in the global pharmaceutical race. Read more

EURACTIV - Europe's race to phase out combustion-engine cars by 2035 has split opinion over how the transition should unfold. While the EU advances battery electric vehicles (BEVs) as the cornerstone of its Green Deal and industrial strategy, automakers, suppliers, and energy companies warn that an electric-only path could backfire. Read more

EURACTIV - Jérôme Van Biervliet, managing director of Belgium's VIB, has called on Brussels to make access to capital the centrepiece of its forthcoming Biotech Act, warning that Europe's fragmented markets risk driving innovation overseas. Read more

EURACTIV - The European Commission will set out a roadmap early next year to phase out animal testing in safety assessments, a long-awaited plan that will require close coordination between regulators, industry, and international partners to succeed. Read more

EURACTIV - Brain health is the EU's leading cause of disability, yet it's among its least-supported fields. But now, Europe's ongoing health and research reforms could mark a turning point for brain health. The European Brain Council (EBC) and MEP Tomislav Sokol say the EU must now build the investment, coordination and collaboration framework...

EU PERSPECTIVES - Less bureaucratic paperwork and protection on a par with that of energy and defence is what key pharma figures want from the Critical Medicines Act (CMA). The legislation, awaiting a 2 December plenary vote, is to secure Europe's medicine supply by reinforcing EU manufacturing and cutting red tape. Read more

EU PERSPECTIVES - Determined not to repeat the chaos of Covid-19, the European Union is keeping its vaccine engine running between crises. The blueprint links Europe's vaccine research hub with a network of factories and a new financing approach. It promises to turn pandemic readiness into permanent capacity. Read more

EURACTIV - Belgium has become a focal point in Europe's biotech debate after the biotech company Galapagos halted development of its advanced cell therapy programme. The move follows similar withdrawals by Takeda and Novo Nordisk, both of which ended their cell therapy operations to refocus on core areas. Read more